Hepatitis C Flashcards
Hepatitis C virus:
- type
- incubation period
- hepatitis C is RNA flavivirus
- incubation period: 6-9 weeks
Progression of Hepatitis C infection
- some people clear the virus naturally
- those who do not → may: remain free of symptoms; develop liver cirrhosis or cancer
Is there a vaccine for Hepatitis C?
No
Transmission of Hep C risks for:
- needle stick injury
- vertical transmission
- sexual intercourse
- needle stick injury → about 2% risk
- vertical transmission rate from mother to child → about 6% ( risk is higher if there is coexistent HIV)
- sexual intercourse → less than 5%
Is breastfeeding contraindicated in mums with hepatitis C?
Breastfeeding is not contraindicated in mums with hepatitis C
What do the majority of Hep C causes come from?
IVDU (90% cases)
Structure of Hepatitis C virus
Symptoms of acute Hepatitis C infection
After exposure to the hepatitis C virus only around 30% of patients will develop features such as:
- a transient rise in serum aminotransferases / jaundice
- fatigue
- arthralgia
(jaundice + flu-like illness)
Investigations for Hepatitis C infection
- HCV RNA → to diagnose acute infection
(HCV RNA can be detected in blood 1-3 weeks after initial exposure)
What can be seen in the blood results of a patient infected with Hepatitis C? (2)
- HCV RNA → detected 1-3 weeks after initial exposure (diagnostic of Hep C)
- patients will eventually develop anti-HCV antibodies
* patients who spontaneously clear the virus will continue to have anti-HCV antibodies
How many patients will develop chronic Hep C infection?
- around 15-45% of patients will clear the virus after acute infection (depending on their age and underlying health)
- the majority (55-85%) will develop chronic hepatitis C
What’s the definition of chronic Hep C (in terms of blood results)?
persistence of HCV RNA in the blood for 6 months
(2 positive PCR HCV 6 months apart)
Potential complications of chronic Hep C
- rheumatological problems: arthralgia, arthritis
- eye problems: Sjogren’s syndrome
- cirrhosis (5-20% of those with chronic disease)
- hepatocellular cancer
- cryoglobulinaemia: typically type II (mixed monoclonal and polyclonal)
- porphyria cutanea tarda (PCT): it is increasingly recognised that PCT may develop in patients with hepatitis C, especially if there are other factors such as alcohol abuse
- membranoproliferative glomerulonephritis
Management of chronic Hepatitis C
-
- drugs
Drugs: combination of protease inhibitors (e.g. daclatasvir + sofosbuvir or sofosbuvir + simeprevir) with or without ribavirin are used
- treatment depends on the viral genotype - this should be tested prior to treatment
- Treatment success rate 95%